Beta-Blocker Use in Hypertension and Heart Failure (A Secondary Analysis of the Systolic Blood Pressure Intervention Trial)
Given the concern that beta-blocker use may be associated with an increased risk for heart failure (HF) in populations with normal left ventricular systolic function, we evaluated the association between beta-blocker use and incident HF events, as well as loop diuretic initiation in the Systolic Blo...
Gespeichert in:
Veröffentlicht in: | The American journal of cardiology 2022-02, Vol.165, p.58-64 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 64 |
---|---|
container_issue | |
container_start_page | 58 |
container_title | The American journal of cardiology |
container_volume | 165 |
creator | Silverman, Daniel N. de Lavallaz, Jeanne du Fay Plante, Timothy B. Infeld, Margaret M. Goyal, Parag Juraschek, Stephen P. Dougherty, Geoff B. Callas, Peter W. Meyer, Markus |
description | Given the concern that beta-blocker use may be associated with an increased risk for heart failure (HF) in populations with normal left ventricular systolic function, we evaluated the association between beta-blocker use and incident HF events, as well as loop diuretic initiation in the Systolic Blood Pressure Intervention Trial (SPRINT). SPRINT demonstrated that a blood pressure target of |
doi_str_mv | 10.1016/j.amjcard.2021.10.049 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8766945</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002914921011048</els_id><sourcerecordid>2619204087</sourcerecordid><originalsourceid>FETCH-LOGICAL-c495t-40371c44d35db23c11c9d42ae348c6c2a7e31f6dd0d2f1a6a08f7bb1647302393</originalsourceid><addsrcrecordid>eNqFkUFvEzEQhS0EoqHwE0CWuJTDBnvt9a4voLSipFIlkNqeLceepQ4bO7W9kSL-PF4SKuDCyfL4e88z8xB6TcmcEirer-d6szY62nlNalpqc8LlEzSjXSsrKil7imaEkLqSlMsT9CKldblS2ojn6IRxSQQTYoZ-nEPW1fkQzHeI-C4Bdh4v91uIGXxywWPtLV6CjhlfajeMEfDZAt-ACd7quMcLr4d9cgmHHud7wDf7lMPgDC6eweKvEVKaRFc-Q9yBz5PnbXR6ePcSPev1kODV8TxFd5efbi-W1fWXz1cXi-vKcNnkihPWUsO5ZY1d1cxQaqTltQbGOyNMrVtgtBfWElv3VAtNur5drajgLSM1k-wUfTj4bsfVBqwpTUQ9qG10mzKBCtqpv1-8u1ffwk51rRCSN8Xg7GgQw8MIKauNSwaGQXsIY1K1oIRT0jW8oG__QddhjGVHvyhZE066tlDNgTIxpBShf2yGEjXFq9bqGK-a4p3KJd6ie_PnJI-q33kW4OMBgLLPnYOoknHgDVgXwWRlg_vPFz8Bt8m5tA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2619204087</pqid></control><display><type>article</type><title>Beta-Blocker Use in Hypertension and Heart Failure (A Secondary Analysis of the Systolic Blood Pressure Intervention Trial)</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Silverman, Daniel N. ; de Lavallaz, Jeanne du Fay ; Plante, Timothy B. ; Infeld, Margaret M. ; Goyal, Parag ; Juraschek, Stephen P. ; Dougherty, Geoff B. ; Callas, Peter W. ; Meyer, Markus</creator><creatorcontrib>Silverman, Daniel N. ; de Lavallaz, Jeanne du Fay ; Plante, Timothy B. ; Infeld, Margaret M. ; Goyal, Parag ; Juraschek, Stephen P. ; Dougherty, Geoff B. ; Callas, Peter W. ; Meyer, Markus</creatorcontrib><description>Given the concern that beta-blocker use may be associated with an increased risk for heart failure (HF) in populations with normal left ventricular systolic function, we evaluated the association between beta-blocker use and incident HF events, as well as loop diuretic initiation in the Systolic Blood Pressure Intervention Trial (SPRINT). SPRINT demonstrated that a blood pressure target of <120 mm Hg reduced cardiovascular outcomes compared with <140 mm Hg in adults with at least one cardiovascular risk factor and without HF. The lower rate of the composite primary outcome in the 120 mm Hg group was primarily driven by a reduction in HF events. Subjects on a beta blocker for the entire trial duration were compared with subjects who never received a beta blocker after 1:1 propensity score matching. A competing risk survival analysis by beta-blocker status was performed to estimate the effect of the drug on incident HF and was then repeated for a secondary end point of cardiovascular disease death. Among the 3,284 propensity score–matched subjects, beta-blocker exposure was associated with an increased HF risk (hazard ratio 5.86; 95% confidence interval 2.73 to 13.04; p <0.001). A sensitivity analysis of propensity score–matched cohorts with a history of coronary artery disease or atrial fibrillation revealed the same association (hazard ratio 3.49; 95% confidence interval 1.15 to 10.06; p = 0.028). In conclusion, beta-blocker exposure in this secondary analysis was associated with increased incident HF in subjects with hypertension without HF at baseline.</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>DOI: 10.1016/j.amjcard.2021.10.049</identifier><identifier>PMID: 34906366</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Acute coronary syndromes ; Adrenergic beta-Antagonists - therapeutic use ; Aged ; Antihypertensive Agents - therapeutic use ; Antihypertensives ; Aortic aneurysms ; Atrial Fibrillation - epidemiology ; Beta blockers ; Blood Pressure ; Cardiovascular disease ; Cardiovascular diseases ; Confidence intervals ; Congestive heart failure ; Coronary artery ; Coronary artery disease ; Coronary Artery Disease - epidemiology ; Coronary vessels ; Diuretics ; Electrocardiography ; Enrollments ; Female ; Fibrillation ; Health hazards ; Health risks ; Heart failure ; Heart Failure - epidemiology ; Heart rate ; Humans ; Hypertension ; Hypertension - drug therapy ; Hypertension - epidemiology ; Incidence ; Male ; Middle Aged ; Morbidity ; Patient Care Planning ; Patients ; Propensity Score ; Proportional Hazards Models ; Risk analysis ; Risk Factors ; Secondary analysis ; Sensitivity analysis ; Sodium Potassium Chloride Symporter Inhibitors - therapeutic use ; Stroke ; Survival analysis ; Vein & artery diseases ; Ventricle ; Vital signs</subject><ispartof>The American journal of cardiology, 2022-02, Vol.165, p.58-64</ispartof><rights>2021</rights><rights>Published by Elsevier Inc.</rights><rights>Copyright Elsevier Limited Feb 15, 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c495t-40371c44d35db23c11c9d42ae348c6c2a7e31f6dd0d2f1a6a08f7bb1647302393</citedby><cites>FETCH-LOGICAL-c495t-40371c44d35db23c11c9d42ae348c6c2a7e31f6dd0d2f1a6a08f7bb1647302393</cites><orcidid>0000-0001-7474-3737 ; 0000-0002-0806-1786 ; 0000-0002-3840-4081 ; 0000-0002-9000-0631 ; 0000-0001-9992-9597 ; 0000-0002-1923-6166</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2619204087?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34906366$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Silverman, Daniel N.</creatorcontrib><creatorcontrib>de Lavallaz, Jeanne du Fay</creatorcontrib><creatorcontrib>Plante, Timothy B.</creatorcontrib><creatorcontrib>Infeld, Margaret M.</creatorcontrib><creatorcontrib>Goyal, Parag</creatorcontrib><creatorcontrib>Juraschek, Stephen P.</creatorcontrib><creatorcontrib>Dougherty, Geoff B.</creatorcontrib><creatorcontrib>Callas, Peter W.</creatorcontrib><creatorcontrib>Meyer, Markus</creatorcontrib><title>Beta-Blocker Use in Hypertension and Heart Failure (A Secondary Analysis of the Systolic Blood Pressure Intervention Trial)</title><title>The American journal of cardiology</title><addtitle>Am J Cardiol</addtitle><description>Given the concern that beta-blocker use may be associated with an increased risk for heart failure (HF) in populations with normal left ventricular systolic function, we evaluated the association between beta-blocker use and incident HF events, as well as loop diuretic initiation in the Systolic Blood Pressure Intervention Trial (SPRINT). SPRINT demonstrated that a blood pressure target of <120 mm Hg reduced cardiovascular outcomes compared with <140 mm Hg in adults with at least one cardiovascular risk factor and without HF. The lower rate of the composite primary outcome in the 120 mm Hg group was primarily driven by a reduction in HF events. Subjects on a beta blocker for the entire trial duration were compared with subjects who never received a beta blocker after 1:1 propensity score matching. A competing risk survival analysis by beta-blocker status was performed to estimate the effect of the drug on incident HF and was then repeated for a secondary end point of cardiovascular disease death. Among the 3,284 propensity score–matched subjects, beta-blocker exposure was associated with an increased HF risk (hazard ratio 5.86; 95% confidence interval 2.73 to 13.04; p <0.001). A sensitivity analysis of propensity score–matched cohorts with a history of coronary artery disease or atrial fibrillation revealed the same association (hazard ratio 3.49; 95% confidence interval 1.15 to 10.06; p = 0.028). In conclusion, beta-blocker exposure in this secondary analysis was associated with increased incident HF in subjects with hypertension without HF at baseline.</description><subject>Acute coronary syndromes</subject><subject>Adrenergic beta-Antagonists - therapeutic use</subject><subject>Aged</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Antihypertensives</subject><subject>Aortic aneurysms</subject><subject>Atrial Fibrillation - epidemiology</subject><subject>Beta blockers</subject><subject>Blood Pressure</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Confidence intervals</subject><subject>Congestive heart failure</subject><subject>Coronary artery</subject><subject>Coronary artery disease</subject><subject>Coronary Artery Disease - epidemiology</subject><subject>Coronary vessels</subject><subject>Diuretics</subject><subject>Electrocardiography</subject><subject>Enrollments</subject><subject>Female</subject><subject>Fibrillation</subject><subject>Health hazards</subject><subject>Health risks</subject><subject>Heart failure</subject><subject>Heart Failure - epidemiology</subject><subject>Heart rate</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Hypertension - drug therapy</subject><subject>Hypertension - epidemiology</subject><subject>Incidence</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Morbidity</subject><subject>Patient Care Planning</subject><subject>Patients</subject><subject>Propensity Score</subject><subject>Proportional Hazards Models</subject><subject>Risk analysis</subject><subject>Risk Factors</subject><subject>Secondary analysis</subject><subject>Sensitivity analysis</subject><subject>Sodium Potassium Chloride Symporter Inhibitors - therapeutic use</subject><subject>Stroke</subject><subject>Survival analysis</subject><subject>Vein & artery diseases</subject><subject>Ventricle</subject><subject>Vital signs</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkUFvEzEQhS0EoqHwE0CWuJTDBnvt9a4voLSipFIlkNqeLceepQ4bO7W9kSL-PF4SKuDCyfL4e88z8xB6TcmcEirer-d6szY62nlNalpqc8LlEzSjXSsrKil7imaEkLqSlMsT9CKldblS2ojn6IRxSQQTYoZ-nEPW1fkQzHeI-C4Bdh4v91uIGXxywWPtLV6CjhlfajeMEfDZAt-ACd7quMcLr4d9cgmHHud7wDf7lMPgDC6eweKvEVKaRFc-Q9yBz5PnbXR6ePcSPev1kODV8TxFd5efbi-W1fWXz1cXi-vKcNnkihPWUsO5ZY1d1cxQaqTltQbGOyNMrVtgtBfWElv3VAtNur5drajgLSM1k-wUfTj4bsfVBqwpTUQ9qG10mzKBCtqpv1-8u1ffwk51rRCSN8Xg7GgQw8MIKauNSwaGQXsIY1K1oIRT0jW8oG__QddhjGVHvyhZE066tlDNgTIxpBShf2yGEjXFq9bqGK-a4p3KJd6ie_PnJI-q33kW4OMBgLLPnYOoknHgDVgXwWRlg_vPFz8Bt8m5tA</recordid><startdate>20220215</startdate><enddate>20220215</enddate><creator>Silverman, Daniel N.</creator><creator>de Lavallaz, Jeanne du Fay</creator><creator>Plante, Timothy B.</creator><creator>Infeld, Margaret M.</creator><creator>Goyal, Parag</creator><creator>Juraschek, Stephen P.</creator><creator>Dougherty, Geoff B.</creator><creator>Callas, Peter W.</creator><creator>Meyer, Markus</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7Z</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7474-3737</orcidid><orcidid>https://orcid.org/0000-0002-0806-1786</orcidid><orcidid>https://orcid.org/0000-0002-3840-4081</orcidid><orcidid>https://orcid.org/0000-0002-9000-0631</orcidid><orcidid>https://orcid.org/0000-0001-9992-9597</orcidid><orcidid>https://orcid.org/0000-0002-1923-6166</orcidid></search><sort><creationdate>20220215</creationdate><title>Beta-Blocker Use in Hypertension and Heart Failure (A Secondary Analysis of the Systolic Blood Pressure Intervention Trial)</title><author>Silverman, Daniel N. ; de Lavallaz, Jeanne du Fay ; Plante, Timothy B. ; Infeld, Margaret M. ; Goyal, Parag ; Juraschek, Stephen P. ; Dougherty, Geoff B. ; Callas, Peter W. ; Meyer, Markus</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c495t-40371c44d35db23c11c9d42ae348c6c2a7e31f6dd0d2f1a6a08f7bb1647302393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Acute coronary syndromes</topic><topic>Adrenergic beta-Antagonists - therapeutic use</topic><topic>Aged</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Antihypertensives</topic><topic>Aortic aneurysms</topic><topic>Atrial Fibrillation - epidemiology</topic><topic>Beta blockers</topic><topic>Blood Pressure</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Confidence intervals</topic><topic>Congestive heart failure</topic><topic>Coronary artery</topic><topic>Coronary artery disease</topic><topic>Coronary Artery Disease - epidemiology</topic><topic>Coronary vessels</topic><topic>Diuretics</topic><topic>Electrocardiography</topic><topic>Enrollments</topic><topic>Female</topic><topic>Fibrillation</topic><topic>Health hazards</topic><topic>Health risks</topic><topic>Heart failure</topic><topic>Heart Failure - epidemiology</topic><topic>Heart rate</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Hypertension - drug therapy</topic><topic>Hypertension - epidemiology</topic><topic>Incidence</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Morbidity</topic><topic>Patient Care Planning</topic><topic>Patients</topic><topic>Propensity Score</topic><topic>Proportional Hazards Models</topic><topic>Risk analysis</topic><topic>Risk Factors</topic><topic>Secondary analysis</topic><topic>Sensitivity analysis</topic><topic>Sodium Potassium Chloride Symporter Inhibitors - therapeutic use</topic><topic>Stroke</topic><topic>Survival analysis</topic><topic>Vein & artery diseases</topic><topic>Ventricle</topic><topic>Vital signs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Silverman, Daniel N.</creatorcontrib><creatorcontrib>de Lavallaz, Jeanne du Fay</creatorcontrib><creatorcontrib>Plante, Timothy B.</creatorcontrib><creatorcontrib>Infeld, Margaret M.</creatorcontrib><creatorcontrib>Goyal, Parag</creatorcontrib><creatorcontrib>Juraschek, Stephen P.</creatorcontrib><creatorcontrib>Dougherty, Geoff B.</creatorcontrib><creatorcontrib>Callas, Peter W.</creatorcontrib><creatorcontrib>Meyer, Markus</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biochemistry Abstracts 1</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Silverman, Daniel N.</au><au>de Lavallaz, Jeanne du Fay</au><au>Plante, Timothy B.</au><au>Infeld, Margaret M.</au><au>Goyal, Parag</au><au>Juraschek, Stephen P.</au><au>Dougherty, Geoff B.</au><au>Callas, Peter W.</au><au>Meyer, Markus</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Beta-Blocker Use in Hypertension and Heart Failure (A Secondary Analysis of the Systolic Blood Pressure Intervention Trial)</atitle><jtitle>The American journal of cardiology</jtitle><addtitle>Am J Cardiol</addtitle><date>2022-02-15</date><risdate>2022</risdate><volume>165</volume><spage>58</spage><epage>64</epage><pages>58-64</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><abstract>Given the concern that beta-blocker use may be associated with an increased risk for heart failure (HF) in populations with normal left ventricular systolic function, we evaluated the association between beta-blocker use and incident HF events, as well as loop diuretic initiation in the Systolic Blood Pressure Intervention Trial (SPRINT). SPRINT demonstrated that a blood pressure target of <120 mm Hg reduced cardiovascular outcomes compared with <140 mm Hg in adults with at least one cardiovascular risk factor and without HF. The lower rate of the composite primary outcome in the 120 mm Hg group was primarily driven by a reduction in HF events. Subjects on a beta blocker for the entire trial duration were compared with subjects who never received a beta blocker after 1:1 propensity score matching. A competing risk survival analysis by beta-blocker status was performed to estimate the effect of the drug on incident HF and was then repeated for a secondary end point of cardiovascular disease death. Among the 3,284 propensity score–matched subjects, beta-blocker exposure was associated with an increased HF risk (hazard ratio 5.86; 95% confidence interval 2.73 to 13.04; p <0.001). A sensitivity analysis of propensity score–matched cohorts with a history of coronary artery disease or atrial fibrillation revealed the same association (hazard ratio 3.49; 95% confidence interval 1.15 to 10.06; p = 0.028). In conclusion, beta-blocker exposure in this secondary analysis was associated with increased incident HF in subjects with hypertension without HF at baseline.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>34906366</pmid><doi>10.1016/j.amjcard.2021.10.049</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-7474-3737</orcidid><orcidid>https://orcid.org/0000-0002-0806-1786</orcidid><orcidid>https://orcid.org/0000-0002-3840-4081</orcidid><orcidid>https://orcid.org/0000-0002-9000-0631</orcidid><orcidid>https://orcid.org/0000-0001-9992-9597</orcidid><orcidid>https://orcid.org/0000-0002-1923-6166</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0002-9149 |
ispartof | The American journal of cardiology, 2022-02, Vol.165, p.58-64 |
issn | 0002-9149 1879-1913 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8766945 |
source | MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
subjects | Acute coronary syndromes Adrenergic beta-Antagonists - therapeutic use Aged Antihypertensive Agents - therapeutic use Antihypertensives Aortic aneurysms Atrial Fibrillation - epidemiology Beta blockers Blood Pressure Cardiovascular disease Cardiovascular diseases Confidence intervals Congestive heart failure Coronary artery Coronary artery disease Coronary Artery Disease - epidemiology Coronary vessels Diuretics Electrocardiography Enrollments Female Fibrillation Health hazards Health risks Heart failure Heart Failure - epidemiology Heart rate Humans Hypertension Hypertension - drug therapy Hypertension - epidemiology Incidence Male Middle Aged Morbidity Patient Care Planning Patients Propensity Score Proportional Hazards Models Risk analysis Risk Factors Secondary analysis Sensitivity analysis Sodium Potassium Chloride Symporter Inhibitors - therapeutic use Stroke Survival analysis Vein & artery diseases Ventricle Vital signs |
title | Beta-Blocker Use in Hypertension and Heart Failure (A Secondary Analysis of the Systolic Blood Pressure Intervention Trial) |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T13%3A26%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Beta-Blocker%20Use%20in%20Hypertension%20and%20Heart%20Failure%20(A%20Secondary%20Analysis%20of%20the%20Systolic%20Blood%20Pressure%20Intervention%20Trial)&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=Silverman,%20Daniel%20N.&rft.date=2022-02-15&rft.volume=165&rft.spage=58&rft.epage=64&rft.pages=58-64&rft.issn=0002-9149&rft.eissn=1879-1913&rft_id=info:doi/10.1016/j.amjcard.2021.10.049&rft_dat=%3Cproquest_pubme%3E2619204087%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2619204087&rft_id=info:pmid/34906366&rft_els_id=S0002914921011048&rfr_iscdi=true |